PPD and Syrrx entered a collaboration agreement in November 2003 to jointly develop and commercialize Syrrx-designed dipeptidyl peptidase IV (DPP IV) inhibitors for the treatment of diabetes and
The compound, AP5346, utilizes Access’ proprietary polymer drug delivery system to selectively deliver the cytotoxic DACH platinum to tumors. Upon receiving clearance from the FDA, Access plans to
In pre-clinical testing the novel taxane, TPI 287, demonstrated the ability to inhibit tumor cell growth in a number of in-vitro cell lines and has shown superior inhibition
The phase I study evaluated multiple dosing regimens of the CEA-TRICOM vaccines in 58 patients with advanced CEA-expressing tumors. Investigators found that disease stabilization was achieved for at
Currently, Humira (adalimumab) is indicated for the treatment of patients with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more disease-modifying
The pediatric supplemental new drug application (sNDA) proposes expanding the range of the indication to include children down to four years of age. According to Dr Peter Verdru,
The study, named STARS, is a randomized, assessor-blinded, parallel group study that will enroll more than 1,000 multiple sclerosis (MS) patients in North and South America, Europe, Australia,
Arena expects that the initial focus of the collaboration will be on two Arena-discovered molecules in pre-clinical development. Under the collaboration, Arena will receive an upfront payment of
The collaboration is part of a cooperative R&D agreement (CRADA) established with the Walter Reed Army Institute of Research (WRAIR) as part of AVI’s ongoing efforts in biodefense
The National Institutes of Health’s Alzheimer’s disease prevention study revealed that there was no increased cardiovascular risk seen in elderly patients taking Celebrex 400mg daily for up to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.